Where is Nuvation Bio Inc. (NUVB) Headed According to Wall Street Analysts?

Nuvation Bio Inc. (NYSE:NUVB) is one of the best small-cap stocks with huge growth potential. Nuvation Bio Inc. (NYSE:NUVB) announced on February 9 the finalization of a protocol amendment to the ongoing global SIGMA study of safusidenib that expands it to a Phase 3 trial. Safusidenib is a novel, oral, potent, brain-penetrant targeted inhibitor of mutant IDH1, and SIGMA is involved in the evaluation of the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with high-risk or high-grade IDH1-mutant astrocytoma following standard-of-care.

Nuvation Bio Inc. (NYSE:NUVB) stated that the new protocol expands patient eligibility in the registrational portion of the trial and includes those with grades 2 and 3 IDH1-mutant astrocytoma with high-risk features and grade 4 IDH1-mutant astrocytoma, after standard-of-care radiation or chemoradiation and adjuvant temozolomide.

In a separate development, Truist lifted the price target on Nuvation Bio Inc. (NYSE:NUVB) to $13 from $11 on January 27, maintaining a Buy rating on the shares. The update came as part of a broader research note previewing fiscal Q4 earnings in biotech. The firm stated that it believes the Ibtrozi franchise has shown robust opportunity out of the gate, with stronger-than-anticipated uptake positioning Ibtrozi as the ROS1 agent of choice versus competitors despite seasonal headwinds.

Nuvation Bio (NYSE:NUVB) is a biopharmaceutical company that develops therapeutic and differentiated candidates to tackle the gaps in oncology. It is advancing several clinical-stage candidates, including a bromodomain and extra-terminal (BET) inhibitor, a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, and a drug-drug conjugate (DDC).

While we acknowledge the potential of NUVB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.